PMC:7499584 / 13603-14328 JSONTXT

{"project":"2_test","denotations":[{"id":"32829416-32415579-45163186","span":{"begin":136,"end":140},"obj":"32415579"},{"id":"32829416-32367471-45163187","span":{"begin":160,"end":164},"obj":"32367471"},{"id":"32829416-32714563-45163188","span":{"begin":381,"end":385},"obj":"32714563"},{"id":"T46096","span":{"begin":136,"end":140},"obj":"32415579"},{"id":"T36381","span":{"begin":160,"end":164},"obj":"32367471"},{"id":"T29758","span":{"begin":381,"end":385},"obj":"32714563"}],"text":"Heparinoid efficacy\nCoagulopathies and heparin treatment are the subject of several articles regarding the pathology of COVID19 (Becker 2020; Porfidia and Pola 2020), and heparan sulfate derivatives and sulfated oligosaccharides appear from several laboratories to play a role in the binding of spike protein to the ACE2 receptor (Clausen et al. 2020; Kim et al. 2020; Kwon et al. 2020; Mycroft-West et al. 2020; Tandon et al. 2020; Zhang et al. 2020). Thus, heparan sulfate derived or sulfated nonanticoagulant and anticoagulant oligosaccharides and derivatives may be effective interdictors of both viral infectivity and coagulopathies, and FDA-approved heparinoid products should be considered for repurposing for COVID19."}